-
The infectious diseases group at Walter Reed reported the clinical cases of 4 patients who acquired visceral leishmaniasis during deployments to either Afghanistan (two patients) or Iraq (two patients).
-
In this issue: Rosiglitazone (Avandia) implicated in yet another study; Prilosec and Nexium not associated with cardiac events; Anastrozole (Arimidex) shown more effective than tamoxifen for treatment of early-stage breast cancer; antibiotics show no effect on sinusitis; FDA actions.
-
-
In this issue: FDA warnings for existing drugs dominate pharmaceutical news this month.
-
Increasingly, hospitals are being required to make public their surveillance data on hospital-related infections as quality indicators.
-
Lipid abnormalities can be problematic in HIV-positive patients receiving highly active antiretroviral therapy (HAART) due to the risk of premature coronary artery disease developing in susceptible patients.
-
The perception of health care risks motivates behaviors in healthcare workers as well as patients.
-
The FDA has approved a combination of 2 antiretrovirals, abacavir and lamivudine, for the treatment of HIV-1 infections. Each tablet contains 600 mg of abacavir and 300 mg of lamivudine for once daily administration. The combination is marketed by GlaxoSmithKline as Epzicom.
-
The FDA has approved a 5-nitroimidazole for the treatment of trichomoniasis, giardiasis, and amebiasis. Tinidazole, a second-generation nitroimidazole antiprotozoal agent, is marketed as Tindamax by Presutti Laboratories.
-
GEMINI Trial; CAMELOT Trial; INVEST Trial; The Dangers of Vitamin E; FDA Actions.